Literature DB >> 15241338

The biology of Kit in disease and the application of pharmacogenetics.

Cem Akin1, Dean D Metcalfe.   

Abstract

C-kit encodes a transmembrane protein with intrinsic tyrosine kinase activity, which functions as the receptor for stem cell factor. It is expressed on a variety of cell types, including mast cells, hematopoietic progenitor cells, melanocytes, germ cells, and gastrointestinal pacemaker cells. Mutations resulting in alteration of Kit function are associated with diseases involving each of these cells. Recent development of tyrosine kinase inhibitors led to their evaluation as novel therapies for diseases associated with Kit activation. This review will discuss the pathobiology of Kit in human disease, with a particular emphasis on implications for potential targeted treatment strategies in mast cell disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15241338     DOI: 10.1016/j.jaci.2004.04.046

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  20 in total

1.  Mast cell activation disorder masquerading as pure red cell aplasia.

Authors:  Lawrence B Afrin
Journal:  Int J Hematol       Date:  2010-06-08       Impact factor: 2.490

2.  Immunohistochemical evaluation of AKT protein activation in canine mast cell tumours.

Authors:  S Rodriguez; K Fadlalla; T Graham; B Tameru; C D Fermin; T Samuel
Journal:  J Comp Pathol       Date:  2012-01-30       Impact factor: 1.311

Review 3.  Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment.

Authors:  Cem Akin; Peter Valent; Luis Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

Review 4.  Mast cells and mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Blood       Date:  2008-08-15       Impact factor: 22.113

5.  Complex chemoattractive and chemorepellent Kit signals revealed by direct imaging of murine mast cells in microfluidic gradient chambers.

Authors:  Amir Shamloo; Milan Manchandia; Meghaan Ferreira; Maheswaran Mani; Christopher Nguyen; Thomas Jahn; Kenneth Weinberg; Sarah Heilshorn
Journal:  Integr Biol (Camb)       Date:  2013-08       Impact factor: 2.192

6.  Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.

Authors:  A Mayado; C Teodosio; A C Garcia-Montero; A Matito; A Rodriguez-Caballero; J M Morgado; C Muñiz; M Jara-Acevedo; I Álvarez-Twose; L Sanchez-Muñoz; S Matarraz; C Caldas; J I Muñoz-González; L Escribano; A Orfao
Journal:  Leukemia       Date:  2015-07-08       Impact factor: 11.528

Review 7.  Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  Cem Akin
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

8.  Urticaria pigmentosa-like disease in a dog.

Authors:  Marlene S Pariser; Dunbar W Gram
Journal:  Can Vet J       Date:  2015-03       Impact factor: 1.008

Review 9.  Eosinophilia in mast cell disease.

Authors:  Anna Kovalszki; Peter F Weller
Journal:  Immunol Allergy Clin North Am       Date:  2014-03-13       Impact factor: 3.479

10.  Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases.

Authors:  Danielle Canioni; Bénédicte Deau-Fischer; Pierre Taupin; Vincent Ribrag; Richard Delarue; Jacques Bosq; Marie-Thérèse Rubio; Damien Roux; Viorel Vasiliu; Bruno Varet; Nicole Brousse; Olivier Hermine
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.